Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Quantitative Comparison of qPCR vs. ddPCR for Low-Level Viral Vector Shedding Detection in Feces

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Quantitative Comparison of qPCR vs. ddPCR for Low-Level Viral Vector Shedding Detection in Feces

Quantitative Comparison: qPCR vs. ddPCR for Low-Level Viral Vector Shedding

CELL & GENE | RNA | BIOLOGICS

  • Precision Analytics for Regulatory Confidence in Gene Therapy Biodistribution.*

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

Frequently Asked Questions: qPCR vs. ddPCR for Viral Shedding

    Why is ddPCR often preferred for detecting low-level viral shedding?

    Droplet digital PCR (ddPCR) partitions a sample into thousands of individual reactions, allowing for the direct counting of target DNA molecules. This provides absolute quantification without reliance on a standard curve, yielding higher precision and sensitivity for detecting the low copy numbers characteristic of viral shedding in complex matrices like feces.

    How does matrix inhibition in fecal samples affect qPCR versus ddPCR?

    Fecal samples contain potent PCR inhibitors that can significantly impact the amplification efficiency in quantitative PCR (qPCR), leading to underestimation of the target quantity. The partitioning mechanism of ddPCR makes it more tolerant to inhibitors, as the effect is diluted across thousands of droplets, ensuring more reliable quantification from challenging sample types.

    What is the primary difference in data output between the two methods?

    qPCR provides relative or relative-quantitative data, expressed as a quantification cycle (Cq) value that is interpolated against a standard curve to determine concentration. ddPCR provides absolute concentration data, reported as copies per microliter, based on Poisson statistics from positive and negative droplets, removing the potential for variability from standard curve preparation.

    Is one method more accepted by regulatory agencies for IND-enabling studies?

    Both methods are accepted. However, for biodistribution and shedding studies where demonstrating the absence or clearance of vector is the objective, the superior precision and absolute nature of ddPCR at the lower limit of quantification (LLOQ) provides a more robust data package for regulatory review.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Executive Summary

The selection of a bioanalytical method for viral shedding analysis directly impacts the integrity of an Investigational New Drug (IND) application. For detecting low-level adeno-associated virus (AAV) vector DNA in complex matrices like feces, droplet digital PCR (ddPCR) demonstrates superior precision and inhibitor tolerance compared to traditional quantitative PCR (qPCR). This enhanced performance at low analyte concentrations provides a more definitive dataset for evaluating vector clearance and biodistribution, strengthening the safety profile submitted to regulatory bodies. Franklin Biolabs has standardized GxP-compliant ddPCR assays to support programs advancing toward the typical 18-24 month IND timeline.

The Challenge of Quantifying Low-Level Vector Shedding

A comprehensive understanding of vector biodistribution and clearance is a foundational component of any gene therapy safety assessment. Regulatory agencies require robust data demonstrating where the vector distributes post-administration and confirming its clearance from the body over time. Fecal shedding analysis is a primary method for monitoring vector excretion.

The analytical challenge is significant. Vector concentrations in fecal samples are often near the lower limit of quantification, and the sample matrix itself contains numerous PCR inhibitors that can compromise assay performance. An inaccurate or imprecise result can obscure the true clearance kinetics of a vector, creating potential delays during regulatory review.

).*

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

A Direct Comparison of Analytical Methodologies

The choice between qPCR and ddPCR for shedding studies hinges on the need for absolute precision at very low concentrations. While qPCR has long been a standard, its reliance on amplification efficiency makes it vulnerable in inhibitor-rich samples.

As demonstrated in foundational studies (PMID: 24328707), ddPCR overcomes this limitation by partitioning the reaction. This approach provides absolute quantification of vector DNA with high precision, which is invaluable for biodistribution analysis. This level of analytical rigor is complementary to upstream vector optimization efforts, where promoter and capsid selection are tuned for therapeutic efficacy (PMID: 28056565). A well-characterized vector requires an equally well-characterized safety and clearance profile.

“The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

The following table outlines the key operational differences relevant to GxP-compliant viral shedding studies.

Feature Quantitative PCR (qPCR) Droplet Digital PCR (ddPCR)
Quantification Relative (requires standard curve) Absolute (based on Poisson statistics)
Precision Lower at low copy numbers High at low copy numbers
Inhibitor Tolerance Susceptible to matrix inhibitors More robust and tolerant
Primary Output Cq Value Copies / µL
Application Focus High-throughput screening, relative expression Low-level detection, copy number variation, absolute quantification

Implications for IND-Enabling Programs

For a successful IND submission, the bioanalytical data must be unambiguous. By leveraging ddPCR for viral shedding, programs can generate a dataset that more accurately defines the clearance profile of their AAV vector. This reduces the risk of regulatory questions related to assay sensitivity or the influence of matrix effects.

At Franklin Biolabs, our Bioanalytical Services group operates within a robust GxP framework, leveraging validated ddPCR platforms to support our partners’ programs. This commitment to analytical excellence contributes to the high-quality data packages that have supported a 100% IND success rate for programs conducted since 2019. (The Franklin Biolabs brand launched in 2024, continuing the work and success of its core scientific teams).

” ]

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities